Virus Dataset Detail

> Detail information for each sample

Dataset Information
Accession GSE58240
Status 2014/7/30
Title Gene expression profiling of the response to interferon beta in EBV-transformed and primary B cells of patients with multiple sclerosis
Organism Homo sapiens
Experiment type Expression profiling by array
Summary To identify gene expression changes and pathways induced by interferon-β (IFN-β) in B cells, we studied the in vitro response of EBV-transformed B cells (lymphoblast cell lines-LCLs). LCLs were derived from an MS patient repository. Whole genome expression analysis identified 115 genes that were more than two-fold differentially up-regulated following IFN-β exposure, with over 50 novel IFN-β response genes. Pathways analysis demonstrated that IFN-β affected LCLs in a similar manner to other cell types by activating known IFN-β canonical pathways. Additionally, IFN-β increased the expression of innate immune response genes, while down-regulating many B cell receptor pathway genes and genes involved in adaptive immune responses. Several of the novel response genes were tested and validated as IFN-β response genes in human primary B cells.
Samples
GSM ID Sample info Characteristics Description
GSM1404566 LCL_IFN-beta treated_4hr [Y5707] in vitro treated ifnb:Yes; gender:Female; ms subtype:Relapsing Remitting; treatment status at phlebotomy:Naive; age:27; ethnicity (jewish/arab):A -
GSM1404567 LCL_IFN-beta treated_4hr [YM2209] in vitro treated ifnb:Yes; gender:Female; ms subtype:Relapsing Remitting; treatment status at phlebotomy:Treated; age:47; ethnicity (jewish/arab):J -
GSM1404568 LCL_IFN-beta treated_4hr [YM0206] in vitro treated ifnb:Yes; gender:Female; ms subtype:Relapsing Remitting; treatment status at phlebotomy:Naive; age:43; ethnicity (jewish/arab):J -
GSM1404569 LCL_IFN-beta treated_4hr [Y3811] in vitro treated ifnb:Yes; gender:Male; ms subtype:Relapsing Remitting; treatment status at phlebotomy:Treated; age:23; ethnicity (jewish/arab):A -
GSM1404570 LCL_IFN-beta treated_4hr [YM1208] in vitro treated ifnb:Yes; gender:Female; ms subtype:Relapsing Progressive; treatment status at phlebotomy:Treated; age:26; ethnicity (jewish/arab):J -
GSM1404571 LCL_IFN-beta treated_4hr [YM1009] in vitro treated ifnb:Yes; gender:Female; ms subtype:Relapsing Remitting; treatment status at phlebotomy:Naive; age:35; ethnicity (jewish/arab):J -
GSM1404572 LCL_IFN-beta treated_4hr [YM04707] in vitro treated ifnb:Yes; gender:Male; ms subtype:Relapsing Remitting; treatment status at phlebotomy:Treated; age:51; ethnicity (jewish/arab):J -
GSM1404573 LCL_IFN-beta treated_4hr [YM03509] in vitro treated ifnb:Yes; gender:Female; ms subtype:Relapsing Remitting; treatment status at phlebotomy:Treated; age:33; ethnicity (jewish/arab):J -
GSM1404574 LCL_IFN-beta treated_4hr [YM08207] in vitro treated ifnb:Yes; gender:Female; ms subtype:Relapsing Remitting; treatment status at phlebotomy:Treated; age:47; ethnicity (jewish/arab):J -
GSM1404575 LCL_IFN-beta treated_4hr [YM06707] in vitro treated ifnb:Yes; gender:Female; ms subtype:Relapsing Remitting; treatment status at phlebotomy:Treated; age:46; ethnicity (jewish/arab):J -
GSM1404576 LCL_untreated [N5707] in vitro treated ifnb:NO; gender:Female; ms subtype:Relapsing Remitting; treatment status at phlebotomy:Naive; age:27; ethnicity (jewish/arab):A -
GSM1404577 LCL_untreated [NM2209] in vitro treated ifnb:NO; gender:Female; ms subtype:Relapsing Remitting; treatment status at phlebotomy:Treated; age:47; ethnicity (jewish/arab):J -
GSM1404578 LCL_untreated [NM0206] in vitro treated ifnb:NO; gender:Female; ms subtype:Relapsing Remitting; treatment status at phlebotomy:Naive; age:43; ethnicity (jewish/arab):J -
GSM1404579 LCL_untreated [N3811] in vitro treated ifnb:NO; gender:Male; ms subtype:Relapsing Remitting; treatment status at phlebotomy:Treated; age:23; ethnicity (jewish/arab):A -
GSM1404580 LCL_untreated [NM1208] in vitro treated ifnb:NO; gender:Female; ms subtype:Relapsing Progressive; treatment status at phlebotomy:Treated; age:26; ethnicity (jewish/arab):J -
GSM1404581 LCL_untreated [NM1009] in vitro treated ifnb:NO; gender:Female; ms subtype:Relapsing Remitting; treatment status at phlebotomy:Naive; age:35; ethnicity (jewish/arab):J -
GSM1404582 LCL_untreated [NM04707] in vitro treated ifnb:NO; gender:Male; ms subtype:Relapsing Remitting; treatment status at phlebotomy:Treated; age:51; ethnicity (jewish/arab):J -
GSM1404583 LCL_untreated [NM03509] in vitro treated ifnb:NO; gender:Female; ms subtype:Relapsing Remitting; treatment status at phlebotomy:Treated; age:33; ethnicity (jewish/arab):J -
GSM1404584 LCL_untreated [NM08207] in vitro treated ifnb:NO; gender:Female; ms subtype:Relapsing Remitting; treatment status at phlebotomy:Treated; age:47; ethnicity (jewish/arab):J -
GSM1404585 LCL_untreated [NM06707] in vitro treated ifnb:NO; gender:Female; ms subtype:Relapsing Remitting; treatment status at phlebotomy:Treated; age:46; ethnicity (jewish/arab):J -
GSM1404586 LCL_IFN-beta treated_4hr [Y12705] in vitro treated ifnb:Yes; gender:Male; ms subtype:Secondary Progressive; treatment status at phlebotomy:Treated; age:34; ethnicity (jewish/arab):A -
GSM1404587 LCL_IFN-beta treated_4hr [Y4605] in vitro treated ifnb:Yes; gender:Male; ms subtype:Relapsing Remitting; treatment status at phlebotomy:Treated; age:38; ethnicity (jewish/arab):A -
GSM1404588 LCL_IFN-beta treated_4hr [Y6305] in vitro treated ifnb:Yes; gender:Female; ms subtype:Secondary Progressive; treatment status at phlebotomy:Treated; age:20; ethnicity (jewish/arab):A -
GSM1404589 LCL_IFN-beta treated_4hr [Y206] in vitro treated ifnb:Yes; gender:Male; ms subtype:Relapsing Remitting; treatment status at phlebotomy:Treated; age:59; ethnicity (jewish/arab):A -
GSM1404590 LCL_IFN-beta treated_4hr [Y13605] in vitro treated ifnb:Yes; gender:Male; ms subtype:Relapsing Remitting; treatment status at phlebotomy:Treated; age:39; ethnicity (jewish/arab):A -
GSM1404591 LCL_IFN-beta treated_4hr [Y306] in vitro treated ifnb:Yes; gender:Female; ms subtype:Relapsing Remitting; treatment status at phlebotomy:Naive; age:42; ethnicity (jewish/arab):A -
GSM1404592 LCL_untreated [N12705] in vitro treated ifnb:NO; gender:Male; ms subtype:Secondary Progressive; treatment status at phlebotomy:Treated; age:34; ethnicity (jewish/arab):A -
GSM1404593 LCL_untreated [N4605] in vitro treated ifnb:NO; gender:Male; ms subtype:Relapsing Remitting; treatment status at phlebotomy:Treated; age:38; ethnicity (jewish/arab):A -
GSM1404594 LCL_untreated [N6305] in vitro treated ifnb:NO; gender:Female; ms subtype:Secondary Progressive; treatment status at phlebotomy:Treated; age:20; ethnicity (jewish/arab):A -
GSM1404595 LCL_untreated [N206] in vitro treated ifnb:NO; gender:Male; ms subtype:Relapsing Remitting; treatment status at phlebotomy:Treated; age:59; ethnicity (jewish/arab):A -
GSM1404596 LCL_untreated [N13605] in vitro treated ifnb:NO; gender:Male; ms subtype:Relapsing Remitting; treatment status at phlebotomy:Treated; age:39; ethnicity (jewish/arab):A -
GSM1404597 LCL_untreated [N306] in vitro treated ifnb:NO; gender:Female; ms subtype:Relapsing Remitting; treatment status at phlebotomy:Naive; age:42; ethnicity (jewish/arab):A -
Platform GPL10558  : Illumina HumanHT-12 V4.0 expression beadchip
Literature 25025430  
Download Download xCell Data  Download Expression Analysis Data  
xCell Plot
* p<0.05 ** p<0.01